TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05296070: Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

Sponsor: University of Miami · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$3,049,200

Rescue Site Savings

+$2,032,800

Unlock Full NCT05296070 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05296070 Rescue Dossier →